![Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/4/articles/66632/public/66632-PB8-7675-R1.jpg/w300)
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
![Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study | Scientific Reports Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsrep45411/MediaObjects/41598_2017_Article_BFsrep45411_Fig1_HTML.jpg)
Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study | Scientific Reports
![Cancers | Free Full-Text | Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone Cancers | Free Full-Text | Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone](https://www.mdpi.com/cancers/cancers-15-00048/article_deploy/html/images/cancers-15-00048-g001.png)
Cancers | Free Full-Text | Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone
![Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia](https://agendia.com/wp-content/uploads/2021/07/ASCO-2021-ERBasal_LuminalB_final-poster-3.png)
Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia
![IJMS | Free Full-Text | How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects IJMS | Free Full-Text | How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects](https://www.mdpi.com/ijms/ijms-21-08415/article_deploy/html/images/ijms-21-08415-g001.png)
IJMS | Free Full-Text | How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects
![Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden | BMC Cancer | Full Text Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-022-10098-1/MediaObjects/12885_2022_10098_Fig3_HTML.png)
Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden | BMC Cancer | Full Text
![Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors](https://www.spandidos-publications.com/article_images/ol/17/1/ol-17-01-0616-g02.jpg)
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients | Scientific Reports Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-017-12949-5/MediaObjects/41598_2017_12949_Fig1_HTML.jpg)
Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients | Scientific Reports
![Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes | BMC Women's Health | Full Text Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes | BMC Women's Health | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12905-022-01846-3/MediaObjects/12905_2022_1846_Fig3_HTML.png)
Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes | BMC Women's Health | Full Text
![Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study](https://www.frontiersin.org/files/Articles/539252/fonc-10-01470-HTML/image_m/fonc-10-01470-t001.jpg)
Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
![Overall survival depends on tumor subtype and systemic treatment. a... | Download Scientific Diagram Overall survival depends on tumor subtype and systemic treatment. a... | Download Scientific Diagram](https://www.researchgate.net/publication/313897613/figure/fig2/AS:961362691903524@1606218135843/Overall-survival-depends-on-tumor-subtype-and-systemic-treatment-a-Luminal-A-b-luminal.gif)
Overall survival depends on tumor subtype and systemic treatment. a... | Download Scientific Diagram
![Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis](https://www.frontiersin.org/files/Articles/813462/fonc-12-813462-HTML-r1/image_m/fonc-12-813462-g001.jpg)
Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
![Biomedicines | Free Full-Text | Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer Biomedicines | Free Full-Text | Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer](https://www.mdpi.com/biomedicines/biomedicines-10-02931/article_deploy/html/images/biomedicines-10-02931-g001.png)
Biomedicines | Free Full-Text | Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer
![Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy | Scientific Reports Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-04032-x/MediaObjects/41598_2021_4032_Fig1_HTML.png)
Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy | Scientific Reports
![Breast cancer survival in Mexico between 2007 and 2016 in women without social security: a retrospective cohort study - The Lancet Regional Health – Americas Breast cancer survival in Mexico between 2007 and 2016 in women without social security: a retrospective cohort study - The Lancet Regional Health – Americas](https://www.thelancet.com/cms/attachment/6625aeef-31de-4cdc-8b65-a4b6771dddb9/gr1.jpg)
Breast cancer survival in Mexico between 2007 and 2016 in women without social security: a retrospective cohort study - The Lancet Regional Health – Americas
![Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/4/articles/66632/public/66632-PB7-9461-R1.jpg/w300)
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
![Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives | Journal of Clinical Oncology Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2014/jco.2014.56.32.issue-25/jco.2014.56.32.issue-25/20160922/jco.2014.56.32.issue-25.largecover.png)